• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Tamiflu (oseltamivir phosphate) Capsules and Oral Suspension

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) 

 

December 2012

Summary View

 

WARNINGS AND PRECAUTIONS

Limitations of Populations Studied
  • Safety and efficacy of TAMIFLU for treatment of influenza in pediatric patients less than 2 weeks of age have not been established. Safety and efficacy of TAMIFLU for prophylaxis of influenza have not been established for pediatric patients less than 1 year of age.

 

December 2010

Summary View

 

DRUG INTERACTIONS

  • Proposed update on Aspirin/Tamiflu Drug-Drug Interaction

 

November 2010

Summary View

ADVERSE REACTIONS

Postmarketing Experience
  • Hypothermia